Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 13/20 | 0.42 |
| ▸ | CA9 | Q16790 | 13/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.42 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 10/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6455529 | 0.78 | CA12 (0.45) | CA12CA9CA2RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL18050031 | 0.77 | PARP1 (0.42) | KEAP1PARP1 | |
| SCHEMBL18205947 | 0.70 | BID (0.41) | CA12CA9CA2SMN1; SMN2CA1 | |
| SCHEMBL72113 | 0.69 | PARP1 (0.49) | KEAP1PARP1 | |
| SCHEMBL28383366 | 0.69 | BID (0.47) | CA2 | |
| SCHEMBL6555382 | 0.69 | MAPT (0.52) | PARP1 | |
| SCHEMBL162322 | 0.69 | MAPT (0.52) | PARP1 | |
| SCHEMBL28203375 | 0.68 | KDM4E (0.44) | PARP1 | |
| SCHEMBL4931045 | 0.68 | CA9 (0.73) | CA12CA9CA2RAB9ASMN1; SMN2 | |
| SCHEMBL6131533 | 0.68 | TP53 (0.47) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| WO-2007005887-A2 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS, COMPOSITIONS AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | CA12 3565/4885CA9 2903/4885CA2 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.